Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence

From General Health Literacy to Targeted Risk Assessment

For decades, general health and science communication has served as the foundation for public understanding of medical treatments and their outcomes. This legacy context emphasizes broad awareness of therapeutic benefits and risks, often framed within patient education and clinical guidance. In this tradition, discussions of pharmaceutical interventions have focused on their intended effects and the importance of informed consent, without delving into specific disease mechanisms or causal pathways. As this informational heritage evolves, it becomes necessary to address more specialized areas of concern, particularly those arising from occupational and environmental exposures. The transition from general health literacy to focused risk assessment is a natural progression, especially when considering the implications of novel therapies in real-world settings. One such area of emerging interest involves the relationship between exposure to certain immunotherapeutic agents and subsequent health outcomes. Specifically, the connection between Avelumab—a monoclonal antibody used in oncology—and the development of Merkel Cell Carcinoma has prompted scrutiny within occupational health contexts. This pivot from broad health education to targeted exposure analysis reflects a growing need to evaluate how therapeutic substances may intersect with workplace safety and long-term patient risk, without presuming any specific biological mechanisms.

Understanding Avelumab: A Therapeutic Agent, Not a Cause

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The scientific evidence connecting avelumab to Merkel cell carcinoma is not one of causation in the sense of the drug causing the disease. Rather, avelumab is a treatment for MCC. The query's framing of 'Avelumab Merkel Cell Carcinoma Causation' may be misinterpreted; the available evidence consistently describes avelumab as a therapy for MCC, not as a trigger or cause of the disease.

Merkel Cell Carcinoma: Etiology and Treatment Landscape

Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, treatment options are limited. A multicenter study of the prospective skin cancer registry ADOREG reported that response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition in metastatic MCC can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). In avelumab-refractory patients, combined ipilimumab plus nivolumab has been investigated. In a retrospective study at three German academic sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study confirmed that immune checkpoint inhibitors, including avelumab, are approved for advanced MCC, but noted that despite advances, about half of patients progress (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Considerations and Adverse Effects

Regarding adverse effects, avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia due to reactivation of sarcoidosis during treatment with avelumab for metastatic MCC; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune-related complications, it does not cause MCC itself. In terms of risk considerations, the adequacy of warnings regarding avelumab and MCC should focus on the drug's role as a treatment, not a cause. Patients with MCC who are treated with avelumab should be monitored for immune-related adverse events, as well as for disease progression, given that approximately half of patients may not respond or may become refractory (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between avelumab exposure and documented harm, such as immune-related adverse events, can vary; in the reported sarcoidosis case, hypercalcemia occurred during treatment and resolved with intervention (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to subsequent therapy and response is an important clinical consideration, as seen in studies where avelumab-refractory patients were later treated with ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Causation Clarification and Clinical Implications

Causation-related considerations for affected patients should clarify that avelumab is not a cause of MCC but a therapeutic agent. The scientific evidence does not support a causal link between avelumab exposure and the development of MCC. Instead, avelumab is used to treat existing MCC. Patients and clinicians should be aware of the drug's efficacy, its potential immune-related adverse events, and the possibility of resistance or progression, which may require alternative treatments such as combined ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. The scientific evidence consistently describes avelumab as a therapy for MCC, and there is no evidence that it triggers or causes the disease. MCC is associated with ultraviolet light exposure and Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What are the main risks of avelumab treatment?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, about half of patients with advanced MCC may not respond or may become refractory to avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). Monitoring for irAEs and disease progression is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.